AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dierkes, J.
Right arrow Articles by Boeing, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dierkes, J.
Right arrow Articles by Boeing, H.
Agricola
Right arrow Articles by Dierkes, J.
Right arrow Articles by Boeing, H.
American Journal of Clinical Nutrition, Vol. 86, No. 1, 214-220, July 2007
© 2007 American Society for Nutrition


ORIGINAL RESEARCH COMMUNICATION

Plasma pyridoxal-5-phosphate and future risk of myocardial infarction in the European Prospective Investigation into Cancer and Nutrition Potsdam cohort1,2,3

Jutta Dierkes, Cornelia Weikert, Kerstin Klipstein-Grobusch, Sabine Westphal, Claus Luley, Matthias Möhlig, Joachim Spranger and Heiner Boeing

1 From the Institute of Clinical Chemistry and Biochemistry, University Hospital Magdeburg, Magdeburg, Germany (JD, SW, and CL); the Department of Epidemiology, German Institute of Human Nutrition, Nuthetal, Germany (CW, KK-G, and HB); the School of Public Health, University of the Witwatersrand, Parktown, South Africa (KK-G); and the Department of Clinical Nutrition, German Institute of Human Nutrition, Nuthetal, Germany (MM and JS)

Background: Retrospective studies indicate that low concentrations of plasma pyridoxal-5-phosphate (PLP) are associated with cardiovascular events; however, few prospective studies of this issue have been conducted.

Objective: We therefore investigated whether PLP concentrations are independently associated with myocardial infarction (MI) in the European Investigation into Cancer and Nutrition (EPIC) Potsdam Study.

Design: After exclusion of prevalent MI or stroke, incident cases of MI were identified among 26 761 participants (aged 35–65 y at baseline). The current analysis is based on a nested case-cohort study consisting of a control group of 810 subjects without MI or stroke at baseline and a case group of 148 subjects who had an MI during a mean follow-up period of 6.0 ± 1.5 y. Cox proportional hazard models were used to evaluate the association between plasma PLP and risk of MI.

Results: In the age- and sex-adjusted analysis, subjects in the highest quintile of PLP had a significantly reduced risk of MI (hazard ratio: 0.50; 95% CI: 0.29, 0.83). Adjustment for either low-grade inflammation or smoking diminished this association. When both low-grade inflammation and smoking were adjusted for, the association was abolished. In addition, adjustment for established risk factors also abolished the association between PLP and risk of MI.

Conclusion: These findings from a prospective German cohort study suggest that PLP is not independently associated with risk of MI.

Key Words: Cardiovascular disease • epidemiology • vitamin B-6 • inflammation • smoking




This article has been cited by other articles:


Home page
Am. J. Clin. Nutr.Home page
A. T Vasilaki, D. C McMillan, J. Kinsella, A. Duncan, D. S. J O'Reilly, and D. Talwar
Relation between pyridoxal and pyridoxal phosphate concentrations in plasma, red cells, and white cells in patients with critical illness
Am. J. Clinical Nutrition, July 1, 2008; 88(1): 140 - 146.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by The American Society for Nutrition